Top Advisors at the Forbes|SHOOK Top Advisor Summit in Las Vegas made a significant contribution of $1.5 million to fund a potentially lifesaving treatment for children suffering from relapsed high-risk neuroblastoma, one of the deadliest forms of cancer. Children facing this condition have less than a 5% chance of survival, making the donation at the annual event crucial for advancing research and improving outcomes for these young patients.
The Children’s Cancer Research Fund will utilize the funds to push the boundaries of current immunotherapies, making them safer and more effective for children with neuroblastoma. Additionally, the research will pave the way for scientists to explore the application of these therapies in other childhood cancers, offering hope for more effective treatments across a range of pediatric malignancies.
The generous contribution came from a long list of contributors, from individual wealth management professionals to entire teams and family foundations. Their commitment to supporting childhood cancer research demonstrates the impact that collective action can have in driving advancements in medical treatments and ultimately saving lives.
The list of contributors includes names such as Albert J. Angelus III, members of the AUYEUNG WEALTH MANAGEMENT GROUP at MORGAN STANLEY, and the BIAFORE family, among many others. Each individual and team played a part in raising the substantial amount of funding that will be instrumental in advancing research efforts for pediatric cancer treatment.
The donation highlights the power of collaboration and philanthropy in the fight against childhood cancer. By coming together at events like the Forbes|SHOOK Top Advisor Summit, top advisors and wealth management professionals can make a tangible difference in the lives of children battling cancer, offering them hope for a brighter and healthier future.
Through their generosity and support, these advisors are contributing to a cause that is close to many hearts, with the potential to change the landscape of pediatric oncology and improve outcomes for children facing the challenges of relapsed high-risk neuroblastoma and other childhood cancers. Their dedication to making a difference underscores the importance of supporting innovative research and treatments for the most vulnerable members of society.
